End-Stage Disseminated Malignancy

Stem cells have been used to assist patients with cancer for many years. Listed below are some trials investigating the use of stem cells from bone marrow to assist patient recovery. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as End-Stage Disseminated Malignancy

  • Auto Transplant for High Risk or Relapsed Solid Tumor Location: US
    Overview: The purpose of this study being conducted at the Masonic Cancer Centre at the University of Minnesota is to develop the clinical standard of care for patients with a solid cancer that has a high risk of relapse. Following intensive chemotherapy, the patients in the treatment group will be injected with bone marrow derived stem cells. The primary outcome measure is an improvement in overall survival and disease-free rates. The study commenced in October 2011 and expects to recruit 20 subjects. It is expected to be completed by December 2016.
    Link to Clinical Registry
    Trial Design: Therapeutic intervention
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors and Lymphomas Location: US
    Overview: This trial aims to determine whether a combination transfusion of two kinds of donated but matched adult blood stem cells can have a beneficial effect on children with any one of 13 usually fatal solid tumours. The trial is being conducted at St Jude's Children's Hospital in Memphis. To be a participant in this study, the patient will have had to have a tumour that has not responded to treatment (refractory) or has relapsed. Each participant will also need a donor who is matched to them to avoid rejection of the donated cells (identical HLA haplotypes). The stem cells will be collected from the donor's blood following treatment with G-CSF. These stem cells will then be selected to produce two transfusions (one with cells expressing CD 3+ removed and one with cells expressing CD 45RA+ removed). Patients will then receive chemotherapy before receiving the stem cell transfusions on consecutive days. The safety and feasibility of this procedure will be accessed in terms of blood system recovery, infection rates and the one-year survival. The trial started in July 2012 and is expected to conclude in December 2015.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells